Mirna Therapeutics (MIRN) Files $80.5M Common Stock IPO

Mirna Therapeutics, Inc. (Nasdaq: MIRN) filed a registration with the U.S. SEC for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $80.5 million. The company plans to list on the Nasdaq Global Market under the ticker, MIRN.

Underwriters on the offering are Citigroup, Leerink Partners, Oppenheimer & Co., and Cantor Fitzgerald & Co.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. microRNAs are naturally occurring, short ribonucleic acid, or RNA, molecules, or oligonucleotides, that play a critical role in regulating key biological pathways.

More from the company: Misexpression of even a single microRNA can contribute to disease development and tumor suppressor microRNAs are commonly reduced in cancer. Our scientists and others at leading academic institutions have identified numerous tumor suppressor microRNAs that play key roles in preventing normal cells from becoming cancerous and facilitating proper cancer immunosurveillance. We are developing mimics of naturally occurring microRNAs that are designed to restore this tumor suppressor activity and aid appropriate tumor immune response. This approach is known as microRNA replacement therapy. Our lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, is the first microRNA mimic to enter clinical development and has shown preliminary clinical evidence of anti-tumor activity as a single agent in our ongoing Phase 1 clinical trial. miR-34 is one of the most widely published microRNAs and considered a key regulator of oncogenic pathways. We plan to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. We believe that microRNA mimics represent a new paradigm in cancer therapy and have the potential to create a new, important class of effective cancer drugs, that can potentially be used alone or in combination with other cancer therapeutics.

You May Also Be Interested In

• Osprey Acquisition Corp. III raises $300M in Nasdaq IPO
• Cosmos Health buyback reaches 3.42M shares at ~$650,000 spent
• Circle Internet Group sells $20.25M in ARC tokens to institutions